BidaskClub cut shares of TherapeuticsMD (NASDAQ:TXMD) from a sell rating to a strong sell rating in a report issued on Friday morning.
A number of other brokerages have also recently weighed in on TXMD. Morgan Stanley began coverage on TherapeuticsMD in a research report on Friday, September 8th. They set an equal weight rating and a $6.00 price target on the stock. Jefferies Group reissued a buy rating and issued a $15.00 price objective on shares of TherapeuticsMD in a report on Friday, September 8th. Deutsche Bank reissued a buy rating and issued a $10.00 price objective on shares of TherapeuticsMD in a report on Wednesday, September 13th. Cowen reissued an outperform rating and issued a $16.00 price objective (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. Finally, Noble Financial reissued a buy rating on shares of TherapeuticsMD in a report on Thursday, November 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD has an average rating of Buy and an average price target of $14.88.
Shares of TherapeuticsMD (NASDAQ:TXMD) traded down $0.12 during trading on Friday, hitting $5.84. The stock had a trading volume of 1,744,162 shares, compared to its average volume of 3,070,000. The firm has a market cap of $1,240.00, a PE ratio of -14.97 and a beta of 1.06. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30.
In other TherapeuticsMD news, Director Tommy G. Thompson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 23.92% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Amalgamated Bank boosted its stake in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after purchasing an additional 1,322 shares in the last quarter. Principal Financial Group Inc. boosted its stake in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in TherapeuticsMD during the 2nd quarter valued at $157,000. Quantbot Technologies LP bought a new position in TherapeuticsMD during the 3rd quarter valued at $189,000. Finally, Cetera Investment Advisers bought a new position in TherapeuticsMD during the 2nd quarter valued at $214,000. 73.69% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “TherapeuticsMD (TXMD) Downgraded to Strong Sell at BidaskClub” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/12/23/therapeuticsmd-txmd-downgraded-to-strong-sell-at-bidaskclub.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.